Rapid Response to Remdesivir in Hospitalised COVID-19 Patients : A Propensity Score Weighted Multicentre Cohort Study
© 2023. The Author(s)..
INTRODUCTION: Remdesivir is a registered treatment for hospitalised patients with COVID-19 that has moderate clinical effectiveness. Anecdotally, some patients' respiratory insufficiency seemed to recover particularly rapidly after initiation of remdesivir. In this study, we investigated if this rapid improvement was caused by remdesivir, and which patient characteristics might predict a rapid clinical improvement in response to remdesivir.
METHODS: This was a multicentre observational cohort study of hospitalised patients with COVID-19 who required supplemental oxygen and were treated with dexamethasone. Rapid clinical improvement in response to treatment was defined by a reduction of at least 1 L of supplemental oxygen per minute or discharge from the hospital within 72 h after admission. Inverse probability of treatment-weighted logistic regression modelling was used to assess the association between remdesivir and rapid clinical improvement. Secondary endpoints included in-hospital mortality, ICU admission rate and hospitalisation duration.
RESULTS: Of 871 patients included, 445 were treated with remdesivir. There was no influence of remdesivir on the occurrence of rapid clinical improvement (62% vs 61% OR 1.05, 95% CI 0.79-1.40; p = 0.76). The in-hospital mortality was lower (14.7% vs 19.8% OR 0.70, 95% CI 0.48-1.02; p = 0.06) for the remdesivir-treated patients. Rapid clinical improvement occurred more often in patients with low C-reactive protein (≤ 75 mg/L) and short duration of symptoms prior to hospitalisation (< 7 days) (OR 2.84, 95% CI 1.07-7.56).
CONCLUSION: Remdesivir generally does not increase the incidence of rapid clinical improvement in hospitalised patients with COVID-19, but it might have an effect in patients with short duration of symptoms and limited signs of systemic inflammation.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:12 |
|---|---|
| Enthalten in: |
Infectious diseases and therapy - 12(2023), 10 vom: 06. Okt., Seite 2471-2484 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Leegwater, Emiel [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
COVID-19 |
|---|
| Anmerkungen: |
Date Revised 28.10.2023 published: Print-Electronic Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1007/s40121-023-00874-2 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM362948909 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM362948909 | ||
| 003 | DE-627 | ||
| 005 | 20231226092316.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s40121-023-00874-2 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1209.xml |
| 035 | |a (DE-627)NLM362948909 | ||
| 035 | |a (NLM)37801280 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Leegwater, Emiel |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Rapid Response to Remdesivir in Hospitalised COVID-19 Patients |b A Propensity Score Weighted Multicentre Cohort Study |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 28.10.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a © 2023. The Author(s). | ||
| 520 | |a INTRODUCTION: Remdesivir is a registered treatment for hospitalised patients with COVID-19 that has moderate clinical effectiveness. Anecdotally, some patients' respiratory insufficiency seemed to recover particularly rapidly after initiation of remdesivir. In this study, we investigated if this rapid improvement was caused by remdesivir, and which patient characteristics might predict a rapid clinical improvement in response to remdesivir | ||
| 520 | |a METHODS: This was a multicentre observational cohort study of hospitalised patients with COVID-19 who required supplemental oxygen and were treated with dexamethasone. Rapid clinical improvement in response to treatment was defined by a reduction of at least 1 L of supplemental oxygen per minute or discharge from the hospital within 72 h after admission. Inverse probability of treatment-weighted logistic regression modelling was used to assess the association between remdesivir and rapid clinical improvement. Secondary endpoints included in-hospital mortality, ICU admission rate and hospitalisation duration | ||
| 520 | |a RESULTS: Of 871 patients included, 445 were treated with remdesivir. There was no influence of remdesivir on the occurrence of rapid clinical improvement (62% vs 61% OR 1.05, 95% CI 0.79-1.40; p = 0.76). The in-hospital mortality was lower (14.7% vs 19.8% OR 0.70, 95% CI 0.48-1.02; p = 0.06) for the remdesivir-treated patients. Rapid clinical improvement occurred more often in patients with low C-reactive protein (≤ 75 mg/L) and short duration of symptoms prior to hospitalisation (< 7 days) (OR 2.84, 95% CI 1.07-7.56) | ||
| 520 | |a CONCLUSION: Remdesivir generally does not increase the incidence of rapid clinical improvement in hospitalised patients with COVID-19, but it might have an effect in patients with short duration of symptoms and limited signs of systemic inflammation | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Hospitalized patients | |
| 650 | 4 | |a Rapid clinical improvement | |
| 650 | 4 | |a Remdesivir | |
| 700 | 1 | |a Dol, Lisa |e verfasserin |4 aut | |
| 700 | 1 | |a Benard, Menno R |e verfasserin |4 aut | |
| 700 | 1 | |a Roelofsen, Eveline E |e verfasserin |4 aut | |
| 700 | 1 | |a Delfos, Nathalie M |e verfasserin |4 aut | |
| 700 | 1 | |a van der Feltz, Machteld |e verfasserin |4 aut | |
| 700 | 1 | |a Mollema, Femke P N |e verfasserin |4 aut | |
| 700 | 1 | |a Bosma, Liesbeth B E |e verfasserin |4 aut | |
| 700 | 1 | |a Visser, Loes E |e verfasserin |4 aut | |
| 700 | 1 | |a Ottens, Thomas H |e verfasserin |4 aut | |
| 700 | 1 | |a van Burgel, Nathalie D |e verfasserin |4 aut | |
| 700 | 1 | |a Arbous, Sesmu M |e verfasserin |4 aut | |
| 700 | 1 | |a El Bouazzaoui, Lahssan H |e verfasserin |4 aut | |
| 700 | 1 | |a Knevel, Rachel |e verfasserin |4 aut | |
| 700 | 1 | |a Groenwold, Rolf H H |e verfasserin |4 aut | |
| 700 | 1 | |a de Boer, Mark G J |e verfasserin |4 aut | |
| 700 | 1 | |a Visser, Leo G |e verfasserin |4 aut | |
| 700 | 1 | |a Rosendaal, Frits R |e verfasserin |4 aut | |
| 700 | 1 | |a Wilms, Erik B |e verfasserin |4 aut | |
| 700 | 1 | |a van Nieuwkoop, Cees |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Infectious diseases and therapy |d 2012 |g 12(2023), 10 vom: 06. Okt., Seite 2471-2484 |w (DE-627)NLM240483693 |x 2193-8229 |7 nnns |
| 773 | 1 | 8 | |g volume:12 |g year:2023 |g number:10 |g day:06 |g month:10 |g pages:2471-2484 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s40121-023-00874-2 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 12 |j 2023 |e 10 |b 06 |c 10 |h 2471-2484 | ||